Zai Lab’s Partner BMS Confirms KRYSAL-12 Trial Success for Krazati in KRASG12C-Mutated Cancer
Zai Lab Limited, in collaboration with Bristol Myers Squibb, announced significant progress in the fight against lung cancer with...
Pyros Pharmaceuticals Launches Vigpoder™ (Vigabatrin) for Market
Pyros Pharmaceuticals, Inc., a leading company in the development of specialty pharmaceuticals for rare diseases, has announced the availability...
BMS Updates on Phase 3 Yellowstone Trial for Zeposia in Crohn’s Disease
Bristol Myers Squibb (BMY) has reported that a Phase 3 study within the YELLOWSTONE clinical trial program, which was...
FDA Broadens Vemlidy Indication for Pediatric Chronic HBV Treatment
Gilead Sciences, Inc. has announced the U.S. Food and Drug Administration’s (FDA) approval of the supplemental new drug application...
Gilead and Xilio Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have entered into an exclusive license agreement to develop and commercialize XTX301,...
European Commission Approves Keytruda® Plus Chemotherapy for Resectable NSCLC
Merck announced that the European Commission (EC) has approved KEYTRUDA, its anti-PD-1 therapy, for use in combination with platinum-containing...
BMS’s KRYSAL-12 Trial Shows Promise for Krazati in KRASG12C-Mutated NSCLC
Bristol Myers Squibb has announced significant outcomes from its Phase 3 KRYSTAL-12 study, evaluating KRAZATI® (adagrasib) in patients with...
AN2 Therapeutics Resumes Phase 2/3 Trial for EBO-301
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to creating treatments for rare, chronic, and significant infectious diseases, announced...
SecondWave Systems Secures $3M Additional Financing to Advance Ultrasound-Based Anti-Inflammatory Therapy
SecondWave Systems, Inc., an innovative company at the forefront of bio-ultrasonic medicine development, is making significant strides in creating...
Photopharmics Initiates Largest Phototherapy Trial for Parkinson’s Disease
PhotoPharmics, in partnership with the Center for Health + Technology (CHeT) at the University of Rochester Medical Center (URMC),...